Zydus, XOMA enter into licensing agreement for IL-2-Based Immuno-Oncology Therapy Medical Dialogues Bureau11 March 2020 3:30 AM GMTAhmedabad, Emeryville: Zydus Cadila and XOMA Corporation have announced they have entered into a licensing agreement to advance an IL-2-based immuno-on...
AstraZeneca fails to meet target endpoints in Phase II bladder cancer trial Medical Dialogues Bureau10 March 2020 4:00 AM GMTUSA: The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not me...
Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche Medical Dialogues Bureau25 Nov 2019 3:30 AM GMTMedian overall survival for patients with unresectable hepatocellular carcinoma (HCC), or that which cannot be surgically removed, getting Tecentriq an...
AstraZeneca leukemia drug Calquence gets USFDA okay Medical Dialogues Bureau24 Nov 2019 4:30 AM GMTNew Delhi: AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go-ahead for the company's Calquence drug...
FIRST: Roche wins DCGI nod for Atezolizumab to treat small-cell lung cancer Medical Dialogues Bureau22 Nov 2019 6:55 AM GMT'Atezolizumab is the first cancer immunotherapy to receive approval from DCGI in India for the first-line treatment of extensive-stage small-cell lung ...
BeiGene gets USFDA approval for lymphoma drug Brukinsa Medical Dialogues Bureau17 Nov 2019 3:50 AM GMTBeiGene tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma enrolled in two studies. About three-quarters were Asian, 21% Caucasi...
Aurobindo Pharma USA recalls heartburn drug Ranitidine over cancer causing impurities Medical Dialogues Bureau10 Nov 2019 4:15 AM GMTAurobindo Pharma is second city-based drug company that has initiated the voluntary recall after the FDA announced an investigation into the reported c...
Shilpa Medicare gets USFDA approval for generic equivalent of cancer drug TARCEVA Farhat Nasim8 Nov 2019 4:30 AM GMTErlotinib Tablets, 25 mg, 100 mg, and 150 mg is a generic equivalent of reference listed drug (RLD) TARCEVA used in the treatment of patients with meta...
New USFDA warning letters show Glenmark, Lupin, Cadila Healthcare in trouble Medical Dialogues Bureau7 Nov 2019 10:50 AM GMTCadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd. and Lupin Ltd. are the latest local medicine makers to be reprimanded by the US Food and Drug Adm...
Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial Medical Dialogues Bureau3 Nov 2019 3:30 AM GMTBristol-Myers Squibb said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to chem...
Tests indicate heartburn drug Zantac does not form carcinogen in users: USFDA Medical Dialogues Bureau2 Nov 2019 4:00 AM GMTZantac sold over-the-counter in the United States by French drugmaker Sanofi SA, and some of its generic versions, have been recalled due to possible N...
Mirati Therapeutics oral drug MRTX849 shrinks tumours in early-stage trial Medical Dialogues Bureau2 Nov 2019 3:30 AM GMTOut of 17 patients enrolled in the Phase 1 trial of Mirati Therapeutics' oral drug MRTX849, 12 have been evaluated, including six with lung cancer and ...
